Table 4. Different EDSS outcome in RRMS patients according to the presence of anti-Gal-8 autoantibodies.

Relapsing-Remitting Multiple Sclerosis	Anti-Gal-8 (+) n = 17	Anti-Gal-8 (-) n = 19	Mann-Whitney U test p Value
Disease Duration (years) since first symptoms to baseline; Median (range)	2.0 (1–16)	3.0 (1–9)	0.54
Follow-up (years) since baseline to last assessment Median (range)	1.1 (0.1–1.8)	1.8 (0.1–2.4)	0.62
Annualized relapse rate Median (range)	0.8 (0.1–1.7)	0.6 (0.2–1.9)	0.24
Baseline EDSS (Scale 0–10); Median (range)	0.0 (0.0–1.5)	0.0 (0.0–2.0)	0.93
Final EDSS (Scale 0–10); Median (range)	1.5 (0.0–5.0)	0 (0.0–1.5)	0.02

RRMS: Relapsing-remitting multiple sclerosis; SD: Standard deviation. Mann-Whitney U test. Evolution is independent of relapse number and associates with the presence of anti-Gal-8 autoantibodies. Patients with anti-Gal-8 autoantibodies had worse EDSS.